SynthesisAsian Pacific journal of cancer prevention : APJCP2025
Long Non-Coding RNA SNHG22 in Prognosis for Solid Tumors: A Systematic Review and Meta-Analysis.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSmall nucleolar RNA host gene 22 (SNHG22) is a novel long non-coding RNA (lncRNA) that functions as an oncogene and promotes the progression of various cancers. This pooled analysis aimed to clarify the prognostic role of SNHG22 in solid tumors and to explore its correlation with disease characteristics.
methodsWe conducted a comprehensive search in databases such as PubMed/MEDLINE, Web of Science, Cochrane Library, and Google Scholar for relevant articles published until January 8, 2025. We combined individual data to estimate the overall hazard ratio (HR) for cancer prognosis. Additionally, We assessed the relationships between SNHG22 expression levels and patient characteristics using the odds ratio (OR).
resultsNine studies involving 779 patients participated in the analysis. Patients with SNHG22 overexpression exhibited poorer overall survival (HR=2.44, 95% confidence interval [CI]: 1.98-3.01, I2=0%) and recurrence-free survival (HR=2.60, 95%CI: 1.69-4.00, I2=0%) compared to those with lower levels. Furthermore, higher SNHG22 expression was significantly associated with larger tumor size (OR=2.65, 95%CI: 1.13-6.22), lymph node metastasis (OR=2.12, 95%CI: 1.16-3.86), and advanced disease stages (OR=2.54, 95%CI: 1.73-3.72).
conclusionThe upregulation of SNHG22 is associated with shorter survival outcomes, increased tumor size, lymph node metastases, and more advanced tumor stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.